Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy.

[1]  M. Cooper,et al.  Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-β in a murine diabetic model of atherosclerosis , 2009, Diabetologia.

[2]  Merlin C. Thomas,et al.  Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes , 2008, Diabetes.

[3]  M. V. Dinther,et al.  Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. , 2008, Kidney international.

[4]  H. Schnaper,et al.  MAP-kinase activity necessary for TGFβ1-stimulated mesangial cell type I collagen expression requires adhesion-dependent phosphorylation of FAK tyrosine 397 , 2007, Journal of Cell Science.

[5]  Jing Qing,et al.  TGF‐β activates Erk MAP kinase signalling through direct phosphorylation of ShcA , 2007 .

[6]  G. Tesch,et al.  Rodent models of streptozotocin‐induced diabetic nephropathy (Methods in Renal Research) , 2007 .

[7]  M. Cooper,et al.  Antiproliferative Autoantigen CDA1 Transcriptionally Up-regulates p21Waf1/Cip1 by Activating p53 and MEK/ERK1/2 MAPK Pathways* , 2007, Journal of Biological Chemistry.

[8]  Merlin C. Thomas,et al.  Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. , 2006, Journal of the American Society of Nephrology : JASN.

[9]  D. Nikolic-Paterson,et al.  Recent Insights into Experimental Mouse Models of Diabetic Nephropathy , 2006, Nephron Experimental Nephrology.

[10]  M. Jinnin,et al.  Characterization of SIS3, a Novel Specific Inhibitor of Smad3, and Its Effect on Transforming Growth Factor-β1-Induced Extracellular Matrix Expression , 2006, Molecular Pharmacology.

[11]  M. Cooper,et al.  Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. , 2005, Journal of the American Society of Nephrology : JASN.

[12]  Merlin C. Thomas,et al.  Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. , 2004, Journal of the American Society of Nephrology : JASN.

[13]  M. Cooper,et al.  The time has come to target connective tissue growth factor in diabetic complications , 2004, Diabetologia.

[14]  A. De Siervi,et al.  UCN-01-Induced Cell Cycle Arrest Requires the Transcriptional Induction of p21waf1/cip1 by Activation of Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase Pathway , 2004, Cancer Research.

[15]  L. Truong,et al.  Advanced glycation end products activate Smad signaling via TGF‐β‐dependent and ‐independent mechanisms: implications for diabetic renal and vascular disease , 2004 .

[16]  F. Ziyadeh,et al.  Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. , 2003, Seminars in nephrology.

[17]  H. Schnaper,et al.  Cross‐talk between ERK MAP kinase and Smad‐signaling pathways enhances TGF‐β dependent responses in human mesangial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Emile de Heer,et al.  ECM homeostasis in renal diseases: a genomic approach , 2003, The Journal of pathology.

[19]  C. Johnston,et al.  Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy , 2003, Diabetologia.

[20]  S. Dupont,et al.  Links between Tumor Suppressors p53 Is Required for TGF-β Gene Responses by Cooperating with Smads , 2003, Cell.

[21]  N. Wahab,et al.  J Am Soc Nephrol 14: 1358–1373, 2003 Extracellular Matrix Metabolism in Diabetic Nephropathy , 2022 .

[22]  G. Camussi,et al.  Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. , 2003, Diabetes.

[23]  B. Kemp,et al.  Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. , 2003, Diabetes.

[24]  M. Cooper,et al.  Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin , 2003, Journal of hypertension.

[25]  R. Goldschmeding,et al.  Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[26]  C. Tsalamandris,et al.  Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. , 2002, Diabetes care.

[27]  T. Mune,et al.  11β-Hydroxysteroid Dehydrogenase Type 2 Is Expressed in the Human Kidney Glomerulus , 2002 .

[28]  R. Atkins,et al.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.

[29]  A. Mawson,et al.  SET-related Cell Division Autoantigen-1 (CDA1) Arrests Cell Growth* , 2001, The Journal of Biological Chemistry.

[30]  A. Logan,et al.  Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. , 2001, The Journal of endocrinology.

[31]  L. Ozbun,et al.  Identification of differentially expressed nucleolar TGF-beta1 target (DENTT) in human lung cancer cells that is a new member of the TSPY/SET/NAP-1 superfamily. , 2001, Genomics.

[32]  H. Brady,et al.  Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. , 2000, Kidney international.

[33]  K. Sharma,et al.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Xing Shen,et al.  The MEK Pathway Is Required for Stimulation of p21WAF1/CIP1 by Transforming Growth Factor-β* , 1999, The Journal of Biological Chemistry.

[35]  S. Hubchak,et al.  TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. , 1999, Kidney international.

[36]  Gary R. Grotendorst,et al.  Connective tissue growth factor mediates transforming growth factor b-induced collagen synthesis : down-regulation by cAMP , 1999 .

[37]  Takashi Suzuki,et al.  11β-hydroxysteroid dehydrogenase type 2 in human lung : possible regulator of mineralocorticoid action , 1998 .

[38]  Denis Vivien,et al.  Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.

[39]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[40]  J. Hodgin,et al.  A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.

[41]  Stephen J. Elledge,et al.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest , 1994, Cell.

[42]  Jeffrey L. Wrana,et al.  TGFβ signals through a heteromeric protein kinase receptor complex , 1992, Cell.

[43]  G. Jerums,et al.  Nephropathy in Model Combining Genetic Hypertension With Experimental Diabetes: Enalapril Versus Hydralazine and Metoprolol Therapy , 1990, Diabetes.